TrialBMC anesthesiology2025

Efficacy of intraoperative low-dose remimazolam as a third antiemetic agent for preventing early postoperative nausea in high-risk patient: A Randomized controlled trial.

Seongho Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.